{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02065167",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ORTHO -2"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2012-002010-39",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Universidad Autonoma de Madrid",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip",
      "OfficialTitle": "Evaluation of Safety and Feasibility of Bone Marrow Derived Autologous MSCs to Enhance Bone Healing in Patients With Avascular Necrosis of the Femoral Head",
      "Acronym": "ORTHO-2"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2014",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2017",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 12, 2014",
      "StudyFirstSubmitQCDate": "February 14, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 17, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 5, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 14, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Prof Enrique Gomez-Barrena",
        "ResponsiblePartyInvestigatorTitle": "Full Professor and Chair of orthopaedic surgery",
        "ResponsiblePartyInvestigatorAffiliation": "Universidad Autonoma de Madrid"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Universidad Autonoma de Madrid",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose is to assess the safety and feasibility of cellular therapy derived from bone marrow, to help bone healing in patients with avascular necrosis of the hip.",
      "DetailedDescription": "To assess the safety and feasibility of an in situ single injection of a high dose of autologous bone marrow-derived, in vitro expanded Mesenchymal stem cells, and its contribution to the resolution of the early stages of avascular osteonecrosis of the femoral head."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Avascular Necrosis of the Femoral Head"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "avascular necrosis of femoral head",
          "cell therapy",
          "Mesenchymal stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "26",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Cultured autologous Mesenchymal Cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.\n\n20x106 cells per cc in a single administration of 7cc",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Cultured autologous Mesenchymal Cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Cultured autologous Mesenchymal Cells",
            "InterventionDescription": "Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cultured autologous Mesenchymal Cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Complication rate",
            "PrimaryOutcomeDescription": "Includes early local complication rate plus global complication rate, as the percentage of patients with local or general complications at 52 weeks.",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "complication rate",
            "SecondaryOutcomeDescription": "Local and general complication rate",
            "SecondaryOutcomeTimeFrame": "6,12,24,104 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Progression of disease to the next stage",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Amount of necrotic bone in the femoral head in MRI",
            "SecondaryOutcomeTimeFrame": "12 weeks and 52 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Pain (VAS)",
            "SecondaryOutcomeTimeFrame": "6,12,24,52,104 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "serum levels of bone turnover markers",
            "SecondaryOutcomeTimeFrame": "12 and 24 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge 18 to 65, both sexes\n\nEarly avascular necrosis of the fem oral head (MRI diagnosis): Ficat and Arlet 0, 1, or 2 (Steinberg stages 0, I, IIA, IIB, or IIC)\nSym ptom atic osteonecrosis with less than 6 months of evolution\nAble to provide informed consent, and signed informed consent\nMedical health care coverage\n\nExclusion Criteria:\n\nPregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control.\nParticipation in another therapeutic trial in the previous 3 m onths\nStages 3 or m ore (Ficat and Arlet) or III or m ore (Steinberg) of severe fem oral head osteonecrosis,primarily based on diagnosis by im aging (X-Rays, MRI).\nFlattening or collapse of the fem oral head (Steinberg stage IV) or articular cartilage collapse at the time of core decompression surgery.\nSeptic arthritis.\nStress fracture.\nNon-osteonecrosis metabolic bone diseases (particularly Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism , fibrous dysplasia monostotic, polyostotic McCune-Albright syndrome] and osteopetrosis).\nAny active bisphosphonate treatment or any history of intravenous (IV) treatment.\nHistory of prior or concurrent diagnosis of HIV-, Hepatitis-B- or Hepatitis-C-infection\nActive hepatitis B or hepatitis C infection at the time of screening.\nKnown allergies to products involved in the production process of MSC.\nHistory of neoplasia or current neoplasia in any organ.\nCorticoid or immunosuppressive therapy more than one week in the two months prior to study inclusion\nPatients who will require continuous, systemic, high dose corticosteroid therapy (more than 7.5 m g/day) within 6 months after surgery.\nPatients who are in active treatment for cancer or blood dyscrasia, or have received chemotherapy, radiotherapy or immunotherapy in the past 2 years.\nHistory of regular alcohol consumption exceeding 2 drinks/day within 6 months of screening and/or history of illicit drug use.\nSerum AST (SGO T)/ALT (SGPT) > 2.5 X (institutional standard range).\nMRI-incompatible internal devices (pacemakers, aneurysm clips, etc).\nBody mass index (BMI) of 40 kg/m ² or greater.\nPatients unable to tolerate general anesthesia defined as an American Society of Anesthesiologists (ASA) criteria of > 2.\nInsulin dependent diabetes\nPatients with poorly controlled diabetes mellitus (HbA1C > 8%), or with peripheral neuropathy, or known concomitant vascular problems.\nPatients receiving treatment with hematopoietic growth factors or anti-vasculogenesis or antiangiogenesis treatment.\nTraumatic osteonecrosis.\nAdult in the care of a guardian (Subject legally protected)\nIm possibility to meet at the appointments for the clinical follow up.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Enrique Gomez-Barrena, Prof",
            "OverallOfficialAffiliation": "Universidad Autonoma de Madrid, Hospital la Paz",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Orthopaedic Surgery, Hôpital Henri Mondor",
            "LocationCity": "Créteil",
            "LocationZip": "94000",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "Department of Orthopaedic Surgery, CHU Tours",
            "LocationCity": "Tours",
            "LocationZip": "37044",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "University Children's Hospital",
            "LocationCity": "Tübingen",
            "LocationZip": "72076",
            "LocationCountry": "Germany"
          },
          {
            "LocationFacility": "Department of Orthopaedic Trauma, University of Ulm",
            "LocationCity": "Ulm",
            "LocationZip": "8907581",
            "LocationCountry": "Germany"
          },
          {
            "LocationFacility": "Istituto Ortopedico Rizzoli",
            "LocationCity": "Bologna",
            "LocationZip": "40136",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Servicio de Cirugía Ortopédica y Traumatología \"A\", Hospital La Paz",
            "LocationCity": "Madrid",
            "LocationZip": "28046",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "33535589",
            "ReferenceType": "result",
            "ReferenceCitation": "Gómez-Barrena E, Padilla-Eguiluz NG, Rosset P, Hernigou P, Baldini N, Ciapetti G, Gonzalo-Daganzo RM, Avendaño-Solá C, Rouard H, Giordano R, Dominici M, Schrezenmeier H, Layrolle P, On Behalf Of The Reborne Consortium. Osteonecrosis of the Femoral Head Safely Healed with Autologous, Expanded, Bone Marrow-Derived Mesenchymal Stromal Cells in a Multicentric Trial with Minimum 5 Years Follow-Up. J Clin Med. 2021 Feb 1;10(3). pii: 508. doi: 10.3390/jcm10030508."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010020",
            "ConditionMeshTerm": "Osteonecrosis"
          },
          {
            "ConditionMeshId": "D000005271",
            "ConditionMeshTerm": "Femur Head Necrosis"
          },
          {
            "ConditionMeshId": "D000009336",
            "ConditionMeshTerm": "Necrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000001847",
            "ConditionAncestorTerm": "Bone Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11436",
            "ConditionBrowseLeafName": "Necrosis",
            "ConditionBrowseLeafAsFound": "Necrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M12095",
            "ConditionBrowseLeafName": "Osteonecrosis",
            "ConditionBrowseLeafAsFound": "Avascular Necrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7561",
            "ConditionBrowseLeafName": "Femur Head Necrosis",
            "ConditionBrowseLeafAsFound": "Avascular Necrosis of the Femoral Head",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4278",
            "ConditionBrowseLeafName": "Bone Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          }
        ]
      }
    }
  }
}